StockMarketWire.com - Diurnal Group, the speciality pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will announce its maiden results for the six months ended 31 December on 30 March.


At 3:09pm: [LON:DNL] Diurnal Group Plc Ord Gbp0.05 share price was 0p at 146.5p



Story provided by StockMarketWire.com